EMA Recommends Extension of Therapeutic Indications for Ponatinib By Ogkologos - February 27, 2026 3 0 Facebook Twitter Google+ Pinterest WhatsApp Source RELATED ARTICLESMORE FROM AUTHOR Rare Disease Day 2026: Advancing equity for people living with rare cancers in Europe Updated Oncogene-Addicted mNSCLC Living Guideline v1.3 FDA Approves Pembrolizumab with Paclitaxel for Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma MOST POPULAR A Large Case-Control Study of Hodgkin Lymphoma Survivors Suggests a Dose-Response... February 16, 2023 Neoadjuvant Ipilimumab Plus Nivolumab Results in Longer EFS Than Adjuvant Nivolumab... June 10, 2024 Sheriff’s Sergeant Is Now Fighting Stage III Breast Cancer After Missing... July 16, 2021 The award-winning team transforming breast cancer treatment April 10, 2022 Load more HOT NEWS Cancer and the Holidays Updated Oncogene-Addicted mNSCLC Living Guideline v1.3 Inequalities cause 2,000 extra cancer cases in Wales Genetic discovery could guide treatment for aggressive childhood cancer
